NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage...
– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled...
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage...
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage...
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage...
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases –...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.